159 related articles for article (PubMed ID: 31106145)
1. Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway.
Shang L; Wei M
Front Oncol; 2019; 9():306. PubMed ID: 31106145
[TBL] [Abstract][Full Text] [Related]
2. Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells.
Feng X; Liu H; Zhang Z; Gu Y; Qiu H; He Z
J Exp Clin Cancer Res; 2017 Sep; 36(1):123. PubMed ID: 28886730
[TBL] [Abstract][Full Text] [Related]
3. Lysine methyltransferase Smyd2 suppresses p53-dependent cardiomyocyte apoptosis.
Sajjad A; Novoyatleva T; Vergarajauregui S; Troidl C; Schermuly RT; Tucker HO; Engel FB
Biochim Biophys Acta; 2014 Nov; 1843(11):2556-62. PubMed ID: 25014164
[TBL] [Abstract][Full Text] [Related]
4. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of SMYD2 protects against cisplatin-induced acute kidney injury in mice.
Cui B; Hou X; Liu M; Li Q; Yu C; Zhang S; Wang Y; Wang J; Zhuang S; Liu F
Front Pharmacol; 2022; 13():829630. PubMed ID: 36046818
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA
Liu Z; Wang Q; Bi Y; Chubarov AS; Li Y; Liu L; Yang X; Dmitrienko EV; Zheng Y
J Thorac Dis; 2023 Apr; 15(4):2198-2212. PubMed ID: 37197522
[TBL] [Abstract][Full Text] [Related]
8. Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
Galván-Femenía I; Guindo M; Duran X; Calabuig-Fariñas S; Mercader JM; Ramirez JL; Rosell R; Torrents D; Carreras A; Kohno T; Jantus-Lewintre E; Camps C; Perucho M; Sumoy L; Yokota J; de Cid R
Cancer Treat Res Commun; 2018; 15():21-31. PubMed ID: 30207284
[TBL] [Abstract][Full Text] [Related]
9. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
Huang RS; Zheng YL; Zhao J; Chun X
Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
[TBL] [Abstract][Full Text] [Related]
10. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway.
Jiang P; Xu H; Xu C; Chen A; Chen L; Zhou M; Haq IU; Wu X; Mariyam Z; Feng Q
Chem Biol Interact; 2018 Dec; 296():154-161. PubMed ID: 30291867
[TBL] [Abstract][Full Text] [Related]
11. The selective activation of p53 target genes regulated by SMYD2 in BIX-01294 induced autophagy-related cell death.
Fan JD; Lei PJ; Zheng JY; Wang X; Li S; Liu H; He YL; Wang ZN; Wei G; Zhang X; Li LY; Wu M
PLoS One; 2015; 10(1):e0116782. PubMed ID: 25562686
[TBL] [Abstract][Full Text] [Related]
12. Olean-28,13b-olide 2 plays a role in cisplatin-mediated apoptosis and reverses cisplatin resistance in human lung cancer through multiple signaling pathways.
Zhu B; Ren C; Du K; Zhu H; Ai Y; Kang F; Luo Y; Liu W; Wang L; Xu Y; Jiang X; Zhang Y
Biochem Pharmacol; 2019 Dec; 170():113642. PubMed ID: 31541631
[TBL] [Abstract][Full Text] [Related]
13. STUB1-SMYD2 Axis Regulates Drug Resistance in Glioma cells.
Pan K; Hu B; Wang L; Yuan J; Xu W
J Mol Neurosci; 2022 Sep; 72(9):2030-2044. PubMed ID: 35939202
[TBL] [Abstract][Full Text] [Related]
14. Induction of p53 Phosphorylation at Serine 20 by Resveratrol Is Required to Activate p53 Target Genes, Restoring Apoptosis in MCF-7 Cells Resistant to Cisplatin.
Hernandez-Valencia J; Garcia-Villa E; Arenas-Hernandez A; Garcia-Mena J; Diaz-Chavez J; Gariglio P
Nutrients; 2018 Aug; 10(9):. PubMed ID: 30142917
[TBL] [Abstract][Full Text] [Related]
15. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
[TBL] [Abstract][Full Text] [Related]
16. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway.
Ma LY; Xie XW; Ma L; Pang JL; Xiong XM; Zheng HD; Shen XL; Wen ZG; Wang HY
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2626-2634. PubMed ID: 28678322
[TBL] [Abstract][Full Text] [Related]
17. The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.
Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Kawata A; Honjoh H; Kawata Y; Kashiyama T; Sato M; Taguchi A; Miyamoto Y; Tanikawa M; Tsuruga T; Nagasaka K; Wada-Hiraike O; Osuga Y; Fujii T
Oncol Lett; 2020 Nov; 20(5):153. PubMed ID: 32934721
[TBL] [Abstract][Full Text] [Related]
18. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
19. p53 Affects PGC1α Stability Through AKT/GSK-3β to Enhance Cisplatin Sensitivity in Non-Small Cell Lung Cancer.
Deng X; Li Y; Gu S; Chen Y; Yu B; Su J; Sun L; Liu Y
Front Oncol; 2020; 10():1252. PubMed ID: 32974127
[TBL] [Abstract][Full Text] [Related]
20. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
